Literature DB >> 26583516

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

Matthew D Hellmann1, Mark G Kris1, Charles M Rudin1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26583516     DOI： 10.1001/jamaoncol.2015.4345

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  22 in total

Review 1.  Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

Authors:  Meng Qiao; Tao Jiang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Authors:  Ashraf Z Badros; Ning Ma; Aaron P Rapoport; Emily Lederer; Alexander M Lesokhin
Journal:  Blood Adv       Date:  2019-06-11

Review 4.  Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Authors:  Saiama N Waqar; Philip D Bonomi; Ramaswamy Govindan; Fred R Hirsch; Gregory J Riely; Vassiliki Papadimitrakopoulou; Dickran Kazandjian; Sean Khozin; Erin Larkins; Dane J Dickson; Shakun Malik; Leora Horn; Andrea Ferris; Alice T Shaw; Pasi A Jänne; Tony S K Mok; Roy Herbst; Patricia Keegan; Richard Pazdur; Gideon M Blumenthal
Journal:  J Thorac Oncol       Date:  2016-07-09       Impact factor: 15.609

5.  A new standard for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

6.  Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Authors:  Omer Ben-Aharon; Racheli Magnezi; Moshe Leshno; Daniel A Goldstein
Journal:  Oncologist       Date:  2019-07-18

7.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Authors:  Charles M Rudin; Mark M Awad; Alejandro Navarro; Maya Gottfried; Solange Peters; Tibor Csőszi; Parneet K Cheema; Delvys Rodriguez-Abreu; Mirjana Wollner; James Chih-Hsin Yang; Julien Mazieres; Francisco J Orlandi; Alexander Luft; Mahmut Gümüş; Terufumi Kato; Gregory P Kalemkerian; Yiwen Luo; Victoria Ebiana; M Catherine Pietanza; Hye Ryun Kim
Journal:  J Clin Oncol       Date:  2020-05-29       Impact factor: 44.544

Review 8.  Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Authors:  M D Hellmann; B T Li; J E Chaft; M G Kris
Journal:  Ann Oncol       Date:  2016-07-25       Impact factor: 32.976

9.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Authors:  Sarah B Goldberg; Azeet Narayan; Adam J Kole; Roy H Decker; Jimmitti Teysir; Nicholas J Carriero; Angela Lee; Roxanne Nemati; Sameer K Nath; Shrikant M Mane; Yanhong Deng; Nitin Sukumar; Daniel Zelterman; Daniel J Boffa; Katerina Politi; Scott N Gettinger; Lynn D Wilson; Roy S Herbst; Abhijit A Patel
Journal:  Clin Cancer Res       Date:  2018-01-12       Impact factor: 12.531

10.  Immunotherapy: Cancer immunotherapy and the value of cure.

Authors:  Joseph C Del Paggio
Journal:  Nat Rev Clin Oncol       Date:  2018-02-20       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.